Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16318443 | 0.93 | PTGES (0.56) | PTGESALOX5 | |
| SCHEMBL16318674 | 0.93 | PTGES (0.53) | PTGESALOX5MEN1MAPTKMT2A | |
| SCHEMBL16318423 | 0.90 | PTGES (0.56) | PTGESALOX5RAF1BRAF | |
| SCHEMBL3702752 | 0.89 | PTGES (0.53) | PTGESALOX5MEN1MAPTKMT2A | |
| SCHEMBL6124850 | 0.89 | PTGES (0.54) | PTGESMEN1MAPTKMT2ARAF1 | |
| SCHEMBL16318566 | 0.89 | PTGES (0.55) | PTGESALOX5MEN1MAPTKMT2A | |
| SCHEMBL16318390 | 0.89 | PTGES (0.53) | PTGESALOX5MEN1MAPTKMT2A | |
| SCHEMBL3703238 | 0.87 | PTGES (0.53) | PTGESPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1971110 | 0.87 | PTGES (0.40) | PTGESENPP1PDE4APDE4BPDE4C | |
| SCHEMBL6124858 | 0.86 | PTGES (0.51) | PTGESMEN1MAPTKMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, MAP4 | PTGES 179/4885ALOX5 3006/4885ENPP1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.